Recent insiders trading at Cardiff Oncology, Inc. Filter ; Gary W Pace Director, Buy 15 Sep 2022, $1.71, $256,500 ; Lale White Director, Option 5 Jul 2022, $2.60 ...SAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced plans to advance the company's lead program to the first-line setting of metastatic ...Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing. Gaps in KRAS-mutated mCRC therapies present a significant unmet need. 40%+ of mCRC patients have a KRAS mutation and therefore do not benefit from targeted therapies (e.g., EGFR inhibitors) in first-line therapy. …Pursuant to a securities purchase agreement between the parties, Pfizer purchased 2.4 million shares of Cardiff Oncology's common stock at a price of $6.22 per share. "This collaborative relationship with Pfizer will support our mission to bring treatment options to patients with difficult-to-treat cancers, ...At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Back. Cardiff Oncology, Inc. (CRDF) Add to watchlist. NasdaqCM - NasdaqCM Real Time Price. Currency in USD. 1.5400-0.0400 (-2.53%) At close: 04 ...Feb 1, 2024 · Biggest stock movers today: Cardiff Oncology, MillerKnoll and more msn.com - September 27 at 10:08 AM: Piper Sandler Sticks to Its Buy Rating for Cardiff Oncology (CRDF) markets.businessinsider.com - September 27 at 10:08 AM: Why Cardiff Oncology Stock Is Rising After Hours benzinga.com - September 26 at 6:24 PM Cardiff Oncology, Inc. (CRDF) will release financial results for Q4 and full year 2023 on February 29, 2024. The company focuses on developing cancer therapies using PLK1 inhibition. A conference call and webcast will be held to discuss the results. ... #4132 Ranked by Stock Gains. N/A Ranked by Dividends. CRDF Latest News. Jan 17, 2024.Jan 20, 2019 · Cardiff Oncology, Inc. (CRDF)创立于1999年，前称Trovagene, Inc. (原NASDAQ:TROV)于2020年5月改为现用名，再之前名为Xenomics, Inc.，于2010年1月改为Trovagene，总部位于美国加州San Diego，全职雇员12人，是一家临床阶段的精准医学肿瘤治疗公司，通过在肿瘤基因组学中利用其专有的 ...Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.Market Cap. $77.3M. Currency in USD. Quote data delayed by at least 15 minutes. Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.Cardiff Oncology, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Cardiff Oncology, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cardiff Oncology, Inc. or its management.Onvansertib effectively targets PLK1. PLK1 is an enzyme over-expressed in many cancer types. It’s been known for decades to to be hijacked by tumor cells allowing uncontrolled growth in the M phase of the cell cycle. We now know PLK1 is involved in the repair of damaged DNA in the S phase of the cell cycle. As chemotherapies and targeted ...Dec 19, 2023 · Most recently, on Friday, September 16th, James E. Levine bought 30,000 shares of Cardiff Oncology stock. The stock was acquired at an average cost of $1.56 per share, with a total value of $46,800.00. Following the completion of the transaction, the chief financial officer now directly owns 60,000 shares of the company's stock, valued at ...Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF Get Free Report) fell 1% on Wednesday . The stock traded as low as $1.47 and last traded at $1.52. 92,775 shares ...Market Cap. $77.3M. Currency in USD. Quote data delayed by at least 15 minutes. May 5, 2023 · As of March 31, 2023, Cardiff Oncology had approximately $97.0 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the first quarter of 2023 ...How Many Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Do Institutions Own? (Simply Wall St.) +11.84%. Aug-05- ...Click here to view our latest scientific presentations including all the recent data from our ongoing clinical trials for treatment of AML, mCRC and mCRPC.Pursuant to a securities purchase agreement between the parties, Pfizer purchased 2.4 million shares of Cardiff Oncology's common stock at a price of $6.22 per share. "This collaborative relationship with Pfizer will support our mission to bring treatment options to patients with difficult-to-treat cancers, ...Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, ... Tesla stock has had a pretty lousy start to 2024.- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it …The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology in 2012. The stock currently trades just under $1.50 a share and sports an approximate market ...The Enterprise Value as of February 2024 (TTM) for Cardiff Oncology, Inc. (CRDF) is 61.67M. According to Cardiff Oncology, Inc.’s latest financial reports and current stock price.The company's current Enterprise Value is 61.67M.This represents a change of 19.41% compared to the average of 51.65M of the last 4 quarters.Cardiff Oncology, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Cardiff Oncology, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cardiff Oncology, Inc. or its management.- Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT -SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it …Oct 13, 2021 · Cardiff is a small oncology firm based in San Diego that is currently in the development phase. The stock currently sells for just under $7.00 a share and sports an approximate $260 million market ...Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends ...6 days ago · Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. Cardiff Oncology Inc () Stock Market info Recommendations: Buy or sell Cardiff Oncology stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Cardiff Oncology share forecasts, stock quote and buy / sell signals below.According to present data Cardiff Oncology's CRDF shares and potentially its …BBG000PXLKM7. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy ... Mar 2, 2023 · --Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. Furthermore, we observed an …Cardiff Oncology, Inc., a clinical-stage oncology company ... รายงานนี้อิงตามรายการเฝ้าดูของผู้คนใน Stock Events ที่ติดตาม CRDF นี่ไม่ใช่คำแนะนำในการลงทุน.How Many Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Do Institutions Own? (Simply Wall St.) +11.84%. Aug-05- ...Cardiff Oncology's stock was trading at $1.48 on January 1st, 2024. Since then, CRDF shares have increased by 13.5% and is now trading at $1.68. View the best growth stocks for 2024 here .Alkermes To Spin-Off Mural Oncology In 2H23. ALKS, $31.48, Market Capitalization: $5.2 billion), a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields ... Costco share fall following results, while Cardiff Oncology and MillerKnoll shares soar, and more moving stocks. Cardiff Oncology Inc. CRDF, +0.62% shares surged 32% on favorable data from two cancer drug trials — metastatic pancreatic ductal adenocarcinoma and small cell lung cancer treatment.Jan 15, 2021 · Shares of Cardiff Oncology ( CRDF -1.14%) were trading 19.8% lower as of 11:44 a.m. EST on Friday. The big drop came after the company presented data from a phase 1b/2 study of onvansertib in ... Rodney Markin, MD, PhD, has been Chairman of the Board since December 2020 and served as a Director from February 2014 to December 2020. He is currently Vice President for Network Development, Nebraska Medicine and Associate Vice Chancellor for Business and Executive Director of the UNeTech Institute at the University of Nebraska Medical …Cardiff Oncology is the first to correctly target PLK1, a target in several solid tumors, ... Jun. 07, 2022 10:51 AM ET Cardiff Oncology, Inc. (CRDF) Stock 33 Comments 5 Likes. E. Roudasev.Jan 31, 2023 · 04/14/2022. 2,475,287. 499,242. 4.95809. Back to CRDF Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported ...The mean historical PE Ratio of Cardiff Oncology, Inc. over the last ten years is -5.16. The current -1.82 PE Ratio has changed -64.72% with respect to the historical average. Over the past ten years (40 quarters), CRDF 's PE Ratio was at its highest in in the June 2018 quarter at -0.38. The PE Ratio was at its lowest in in the December 2013 ...Cardiff Oncology, Inc., a clinical-stage oncology company ... รายงานนี้อิงตามรายการเฝ้าดูของผู้คนใน Stock Events ที่ติดตาม CRDF นี่ไม่ใช่คำแนะนำในการลงทุน.Cardiff Oncology, Inc., a clinical-stage oncology company ... รายงานนี้อิงตามรายการเฝ้าดูของผู้คนใน Stock Events ที่ติดตาม CRDF นี่ไม่ใช่คำแนะนำในการลงทุน.Cardiff Oncology Inc stock performance at a glance. Check Cardiff Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. CRDF Stock Performance. USD USD; Previous close: 1.66: 1.66: Day range: 1.56 - 1.661.56 - 1.66Year range: 0 - 20 - 2Market cap:Cardiff Oncology, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Cardiff Oncology, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Cardiff Oncology, Inc. or its management.See Cardiff Oncology, Inc. (CRDF) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Are you an oncology nurse looking to expand your knowledge and advance your career? Look no further than free online oncology nursing CEU courses. Online learning has revolutionize...Feb 9, 2024 · See Cardiff Oncology, Inc. (CRDF) history of stock splits. Includes date and ratio.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a br...Gaps in KRAS-mutated mCRC therapies present a significant unmet need. 40%+ of mCRC patients have a KRAS mutation and therefore do not benefit from targeted therapies (e.g., EGFR inhibitors) in first-line therapy. …Cardiff Oncology, Inc. - Hold. Zacks' proprietary data indicates that Cardiff Oncology, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the CRDF shares ...Cardiff Oncology is the first to correctly target PLK1, a target in several solid tumors, ... Jun. 07, 2022 10:51 AM ET Cardiff Oncology, Inc. (CRDF) Stock 33 Comments 5 Likes. E. Roudasev.Nov 18, 2021 · Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics.Jan 17, 2024 · Press Releases. Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update. - Management will hold a conference call on Thursday, February 29 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging ... Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for ...Cardiff Oncology (NASDAQ: CRDF) is owned by 12.21% institutional shareholders, 34.59% Cardiff Oncology insiders, and 53.19% retail investors. Robert Merrill ...Oct 25, 2020 · Insiders at Cardiff Oncology Have Bought Stock Recently. There was some insider buying at Cardiff Oncology over the last quarter. Independent Director Gary Pace purchased US$15k worth of shares in ...Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted ...Aug 14, 2023 ... Cardiff Oncology stock has recently rallied to around $2 per share after positive guidance from the FDA on a regulatory path forward for ...Nov 16, 2023 · In September 2023, Cardiff Oncology had US$81m in cash, and was debt-free. In the last year, its cash burn was US$34m. That means it had a cash runway of about 2.4 years as of September 2023. Notably, analysts forecast that Cardiff Oncology will break even (at a free cash flow level) in about 4 years. That means unless the company …SAN DIEGO, September 8, 2021 -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced new …Feb 13, 2024 · What is the target price for Cardiff Oncology (CRDF) stock? A. The latest price target for Cardiff Oncology ( NASDAQ: CRDF) was reported by HC Wainwright & Co. on Friday, August 11, 2023. The ... Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing ... Cardiff Oncology has a market cap or net worth of $75.50 million as of January 12, 2024. Its market cap has increased by 9.74% in one year. Market Cap ... Formula: Market Cap = Stock Price * Shares Outstanding. Full Definition. Related Stocks. Company Market Cap; Genenta Science: 82.89M: BioXcel Therapeutics: 79.91M: AlloVir: …On November 17, 2021, Cardiff Oncology, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Pfizer Inc. ("Pfizer"), pursuant to which the Company agreed to offer, issue and sell to Pfizer, (i) in a registered direct offering (the "Offering"), an aggregate of 2,411,575 shares (the "Common Shares") of common …Recent insiders trading at Cardiff Oncology, Inc. Filter ; Gary W Pace Director, Buy 15 Sep 2022, $1.71, $256,500 ; Lale White Director, Option 5 Jul 2022, $2.60 ...Jul 27, 2004 · The Dividend Yield as of February 2024 (TTM) for Cardiff Oncology, Inc. ( CRDF) is 0%. According to Cardiff Oncology, Inc. ’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of -100.00% compared to the average of 0.17% of the last 4 quarters.Feb 18, 2024 · About the Company. Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic ... Based on short-term price targets offered by two analysts, the average price target for Cardiff Oncology comes to $8.50. The forecasts range from a low of $5.00 ...The new name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer with its development of onvansertib, a first-in-class, third-generation, oral and highly ...Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing.Jan 17, 2024 · Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the findings of ... Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, ... Tesla stock has had a pretty lousy start to 2024.Aug 14, 2023 ... Cardiff Oncology stock has recently rallied to around $2 per share after positive guidance from the FDA on a regulatory path forward for ...Melissa Arnold. February 7, 2024. The stock of Cardiff Oncology Inc (CRDF) has gone up by 17.53% for the week, with a 15.29% rise in the past month and a 63.06% rise in the past quarter. The volatility ratio for the week is 12.60%, and the volatility levels for the past 30 days are 7.73% for CRDF. The simple moving average for the past 20 days ...2 days ago · When is Cardiff Oncology's earnings date? Cardiff Oncology has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 7th, 2024 based off last year's report dates. Learn more on CRDF's earnings history. Cardiff Oncology KRAS Mutation Clinical Trial #NCT03829410 · Patient Support ... Stock Gift Contribution · The WunderGlo Store · The WunderGlo Chocolate Bar&nb...Jan 20, 2019 · Cardiff Oncology, Inc. (CRDF)创立于1999年，前称Trovagene, Inc. (原NASDAQ:TROV)于2020年5月改为现用名，再之前名为Xenomics, Inc.，于2010年1月改为Trovagene，总部位于美国加州San Diego，全职雇员12人，是一家临床阶段的精准医学肿瘤治疗公司，通过在肿瘤基因组学中利用其专有的 ...Jan 17, 2024 · Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the findings of ... Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types ...11055 Flintkote Ave. San Diego, CA 92121. 858-952-7570. LinkedIn; Twitter; Facebook; Contact Us; Terms Of Use; Privacy PolicyAug 10, 2023 · As of June 30, 2023, Cardiff Oncology had approximately $89.4 million in cash, cash equivalents, and short-term investments. Net cash used in operating activities for the second quarter of 2023 ...Cardiff Oncology, Inc., a clinical-stage oncology company ... รายงานนี้อิงตามรายการเฝ้าดูของผู้คนใน Stock Events ที่ติดตาม CRDF นี่ไม่ใช่คำแนะนำในการลงทุน.Feb 9, 2024 · See Cardiff Oncology, Inc. (CRDF) history of stock splits. Includes date and ratio.Find the latest Cardiff Oncology, Inc. (CRDF) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Stock Information NASDAQCRDF Jan 22 Jan 29 Feb 5 Feb 10 Feb 16 $1.40 $1.50 $1.60 $1.70 $1.80 $1.90 1dy 1mo 6mo 1yr 5yr $1.73 Last Price -$0.02 (-1.14%) Change 70.1K Volume $77.3M Market Cap Currency in USD. Quote data …1st Jan Change. 1.74 USD. +4.82%. -3.87%. +17.57%. Nov. 02. Transcript : Cardiff Oncology, Inc., Q3 2023 Earnings Call, Nov 02, 2023. Nov. 02. Cardiff Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, …
Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing. . How to see what apple is charging me for
See the latest Cardiff Oncology Inc stock price (CRDF:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Cardiff Oncology Stock Forecast, CRDF stock price prediction. Price target in 14 days: 2.103 USD. The best long-term & short-term Cardiff Oncology share ...Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is ...Cardiff Oncology, Inc. (Nasdaq: ... Most Read from BloombergApple Dials Back Car’s Self-Driving Features and Delays Launch to 2028China Weighs Stock Market Rescue Package Backed by $278 ...The value each CRDF share was expected to gain vs. the value that each CRDF share actually gained.. Cardiff Oncology (CRDF) reported Q3 2023 earnings per share (EPS) of-$0.22, beating estimates of -$0.28 by 23.28%.In the same quarter last year, Cardiff Oncology's earnings per share (EPS) was-$0.20.Cardiff Oncology is expected to …See Cardiff Oncology, Inc. (CRDF) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Stock information is for historical and informational purposes, and is not intended for trading. Melissa Arnold. February 7, 2024. The stock of Cardiff Oncology Inc (CRDF) has gone up by 17.53% for the week, with a 15.29% rise in the past month and a 63.06% rise in the past quarter. The volatility ratio for the week is 12.60%, and the volatility levels for the past 30 days are 7.73% for CRDF. The simple moving average for the past 20 days ...Market Cap. $77.3M. Currency in USD. Quote data delayed by at least 15 minutes. Contact Email [email protected]. Phone Number +1 858-952-7570. Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA ...Gaps in KRAS-mutated mCRC therapies present a significant unmet need. 40%+ of mCRC patients have a KRAS mutation and therefore do not benefit from targeted therapies (e.g., EGFR inhibitors) in first-line therapy. Current investigational therapies for KRAS-mutated mCRC from Amgen, Mirati only address the G12C mutation, not the most prevalent ... Nov 21, 2021 · Cardiff Oncology is a prime takeover target heading into 2022. The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. Four ... Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerSAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...CARDIFF ONCOLOGY INC. - COMMON STOCK. 1.8050. 09-二月-24 14:59:24. 15 分钟延时. 股票. +0.0050. +0.28%. 今日范围. 1.7600 - 1.8900. ISIN. N/A. 来源. NASDAQ. 报价..